A combination of metformin and clemastine shows promise in repairing myelin for multiple sclerosis treatment

In a small, brightly lit laboratory at the University of Cambridge, promising whispers of hope are emanating from an experimental study that could reshape the future for over 150,000 individuals living with multiple sclerosis (MS) in the UK. Among them is Hannah Threlfell, 43, a mother and curate from Abington, who, after being diagnosed in 2019, joined a clinical trial determined to help pave the way for transformative treatments in MS. “I know being on this trial will make a difference,” she shares, eyes bright with optimism, “even small ripples have long-lasting effects!”

Discovery at the Heart of CCMR-Two

The recent findings presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference by Dr. Nick Cunniffe, a clinical lecturer in Neurology at Cambridge, indicate that a combination of metformin—a drug primarily used for type 2 diabetes—and clemastine, an antihistamine, can enhance myelin repair. This comes as a monumental leap forward in a disease often characterized by debilitating symptoms like fatigue, pain, and issues with mobility.

“I am increasingly sure that remyelination is part of the solution to stopping progressive disability in MS,” Dr. Cunniffe remarked, alluding to the urgent need for new strategies to combat this multifaceted disease. Current treatments primarily focus on managing the immune system but fail to address the gradual nerve damage that leads to permanent disability.

Understanding the Mechanism

According to previous research, including a pivotal study in *Nature Neuroscience*, metformin appears to enhance the effects of clemastine on myelin repair in animal models. The promising animal data led to the phase two clinical trial, known as CCMR-Two, which involved 70 participants diagnosed with relapsing MS.

• Demographics: 70 participants, all with relapsing MS
• Duration: Six months trial period
• Methodology: Half received the drug combination; half received a placebo
• Primary Outcome: Visual evoked potential tests to gauge signaling speed between eyes and brain

The results were striking: while the placebo group experienced a decline in signaling speed over the six months, the drug group maintained stable signaling rates. “These preliminary outcomes are positive, reflecting the potential of the drug combination,” stated Dr. Emma Gray, Director of Research at the MS Society. She emphasized the need for rigorous long-term studies to clarify both efficacy and safety.

Challenges Ahead: Efficacy and Safety

Despite the promising data, scientists caution that the full impact on patient experience remains to be seen. “While improvements in myelin insulation can protect nerve fibers, the short-term subjective experience of participants did not show an immediate benefit,” cautioned Dr. Cunniffe. “The real effects may take time, possibly years, to manifest as improvements in daily functioning and quality of life.”

This perspective aligns with findings from a recent meta-analysis published in the *Journal of Neuroimmunology*, which cites the long-term nature of neurodegenerative disease progression as a crucial factor in studying effective therapies.

The Bigger Picture: A Future Beyond MS

Beyond multiple sclerosis, researchers are optimistic that the insights gained from CCMR-Two could be applicable to other neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease. “Preventing irreversible damage to the brain is critical across all neurodegenerative landscapes,” emphasized Dr. Cunniffe. “The research opens the door to a potential paradigm shift.”

Dr. Gray echoed this sentiment, stating, “We desperately need ways to protect nerves from damage and repair lost myelin. This research gives us real hope.” She outlined a three-fold approach to future research:

• Expanding trials to include diverse populations with varying disease progression.
• Conducting longitudinal studies to ascertain long-term benefits and drawbacks.
• Investigating the combined efficacy of remyelination strategies in conjunction with existing MS therapies.

The funding for CCMR-Two comes from the MS Society’s Stop MS Appeal, which seeks to raise £100 million by 2025 for research initiatives that could fundamentally alter treatment landscapes for MS patients. The impact of such steps could extend well beyond individual conditions.

Voices from the Community

For individuals like Hannah Threlfell, participation in the trial isn’t just about medical advancement; it’s a profoundly personal journey. “Being part of this trial gives me hope not just for myself but for future generations,” she reflects. “The world of MS science is moving forward, and I am here for it.”

The tireless work of researchers and the resilience of participants in trials like CCMR-Two highlight an essential truth: the road to understanding and treating complex conditions like MS is fraught with challenges, yet filled with promise. As we edge closer to potential remyelination therapies, the echoes of hope resound—not just in laboratories, but in the lives of those bravely facing the unknown.

Source: www.cam.ac.uk